Friday, January 19, 2024 3:36:14 PM
Name of person filing:
----------------------------------------------------------------------
BlackRock, Inc.
Item 10. Certifications
By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were acquired and are
held in the ordinary course of business and were not acquired
and are not held for the purpose of or with the effect of changing
or influencing the control of the issuer of the securities and were
not acquired and are not held in connection with or as a participant
in any transaction having that purpose or effect.
Amount beneficially owned:
5786527
Percent of class
17.7%
https://ir.collegiumpharma.com/static-files/f6b9c63d-2fab-4091-a2ae-9e8bb26f4c25
WhaleWisdom has data on the historical performance of buying and selling securities based on a given filer’s past 13D/G filings.
**Not surprisingly, 13D and 13G filings often cause a spike in the price of the targeted stock. Especially if the hedge fund or investor making the filing has a proven history of successful activist investing or stock picking. Stocks targeted by smart money investors with the best stock-picking reputations typically receive the largest post-filing “pop.”
https://whalewisdomalpha.com/13d-13g-filings-profit-from-the-smart-money/index.html
Recent COLL News
- Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER • GlobeNewswire Inc. • 04/29/2024 12:00:00 PM
- Collegium to Report First Quarter 2024 Financial Results on May 9, 2024 • GlobeNewswire Inc. • 04/25/2024 12:00:00 PM
- Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026 • GlobeNewswire Inc. • 04/11/2024 12:00:00 PM
- Collegium to Participate in 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 09:26:41 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/29/2024 10:24:26 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/26/2024 09:39:36 PM
- Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results • GlobeNewswire Inc. • 02/22/2024 09:09:56 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/22/2024 09:03:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 09:01:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 09:15:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 09:14:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 09:14:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 09:14:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 09:13:23 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 05:04:28 PM
- Collegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024 • GlobeNewswire Inc. • 02/08/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/18/2024 09:19:10 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/16/2024 09:20:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 01:03:11 PM
- Collegium Provides 2024 Financial Guidance • GlobeNewswire Inc. • 01/03/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/22/2023 09:36:26 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/21/2023 09:15:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/20/2023 10:51:55 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/20/2023 09:28:33 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM